NeuroBo Pharmaceuticals (NRBO)
(Delayed Data from NSDQ)
$4.60 USD
-0.06 (-1.29%)
Updated May 20, 2024 03:29 PM ET
After-Market: $4.59 -0.01 (-0.22%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
NeuroBo Pharmaceuticals, Inc. [NRBO]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ANA001 Phase 2 Trial Stage Completion Near-Term; 2Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Programs Advancing; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pivot Into COVID-19 Continues; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ANA Therapeutics Acquisition Brings COVID-19 Opportunity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Financial Results Reported; Spending In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Lower-Than-Projected Spending; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: NeuroBo Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Financing Complete; Awaiting Pipeline Updates; Reducing PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|